Alnylam Pharmaceuticals
ALNY
#549
Rank
โ‚น4.092 T
Marketcap
โ‚น30,980
Share price
-2.52%
Change (1 day)
30.37%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น15.44

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น8.25. In 2023 the company made an earnings per share (EPS) of -โ‚น323.49 an increase over its 2022 EPS that were of -โ‚น851.34.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น15.44
2023-โ‚น323.49-62%
2022-โ‚น851.3429.03%
2021-โ‚น659.82-3.36%
2020-โ‚น682.73-8.48%
2019-โ‚น745.967.67%
2018-โ‚น692.8139.74%
2017-โ‚น495.7812.94%
2016-โ‚น438.9638.84%
2015-โ‚น316.16-32.88%
2014-โ‚น471.03259.44%
2013-โ‚น131.05-31.25%
2012-โ‚น190.61

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น674.48 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น339.59 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น3,981 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น251.10-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น66.90-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น21.99-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น57.73 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-โ‚น114.55-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA